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Abstract: The epothilone analog ixabepilone exhibits reduced susceptibility to several 
important tumor survival mechanisms that limit the efficacy of taxanes and anthracyclines. As a 
single agent, ixabepilone has shown promise in metastatic breast cancer when anthracyclines, 
taxanes, or capecitabine have failed; and in early-stage breast cancer that is taxane-naïve or has 
previously received taxanes in the adjuvant or metastatic setting. Compared with capecitabine 
alone, ixabepilone used in combination with capecitabine in patients previously treated with 
and resistant to anthracyclines and taxanes produced a 25% reduction in the risk of disease 
progression. Triple-negative tumors showed particular susceptibility to this doublet. Ixabepilone 
has also demonstrated efficacy as first-line therapy in combination with targeted agents such as 
bevacizumab and trastuzumab. Ongoing investigations should provide insight as to how this 
agent could be integrated into treatment of early-stage disease. In clinical studies, toxicities with 
ixabepilone were manageable and reversible through dose reduction or delay, even in patients 
with extensive or heavily-pretreated disease. Thus, ixabepilone represents a useful addition to 
the therapeutic options available for advanced breast cancer, and it may extend progression-free 
survival in patients with limited treatment options.
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Introduction
Current treatment strategies for breast cancer depend on disease stage, tumor grade, tumor 
hormone receptor status, and whether there is over-expression or amplification of the 
human epidermal growth factor receptor (HER). Because of the availability of numerous 
agents, patients with breast cancer may receive several different lines of treatment 
throughout the course of their disease. Once the disease has reached the metastatic stage, 
therapeutic strategies are chosen because they have the potential to achieve symptom 
palliation while significantly prolonging progression-free survival (PFS).1–7
However, tumors may respond to many available agents by upregulating survival 
pathways.8 These mechanisms can render the tumor resistant to multiple, sometimes 
unrelated classes of therapy, presenting an enormous clinical challenge. If tumor 
resistance develops, the disease may eventually progress despite therapy, necessitat-
ing use of agents that are believed to have no cross resistance to previously used 
drugs, or agents that are able to circumvent such resistance.9,10 Furthermore, some 
patients have innate resistance to a particular drug or regimen and may not respond 
at all.9 Because tumors may adapt to anticancer agents, response rates and survival 
outcomes tend to decrease with each subsequent line of therapy. Given that most 
patients with recurrent breast cancer have already been exposed to an anthracycline Cancer Management and Research 2010:2 170
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(eg, doxorubicin, epirubicin) and a taxane (eg, paclitaxel, 
docetaxel) in the adjuvant setting, there is a need for therapies 
that are noncross-resistant with these two classes of cytotoxic 
agents.
The epothilones comprise a novel class of chemotherapeu-
tic agents that have a low susceptibility to multiple mechanisms 
of tumor survival that can result in treatment failure.11–15 
Currently, ixabepilone is the only epothilone to receive 
approval through the US Food and Drug Administration (FDA) 
for the treatment of patients with locally advanced or metastatic 
breast cancer in combination with capecitabine after failure 
of an anthracycline and a taxane, and as monotherapy after 
failure of an anthracycline, a taxane, and capecitabine. Similar 
to taxanes, epothilones like ixabepilone bind to β-tubulin and 
promote tubulin polymerization and microtubule stabilization, 
leading to cell cycle arrest and tumor cell apoptosis.16 However, 
epothilones may retain activity where taxanes fail, because they 
bind to β-tubulin in a qualitatively different manner than the 
taxanes.17,18 Importantly, ixabepilone retains activity in tumors 
that have upregulated their expression of the class III isotype 
of β-tubulin (βIII-tubulin),19 a condition that has been linked 
to failure of other microtubule-targeting agents such as taxanes 
and vinca alkaloids.20,21 As a class, epothilones also induce 
apoptosis through multiple pathways that appear to be distinct 
for this class of agents, including enhancement of caspase-2 
activity and p53-mediated activation of the death effector 
Bax.15 In contrast, taxanes induce apoptosis mainly through 
caspase 9 activation.15
Additionally, in preclinical studies with tumor cell models 
and xenografts, ixabepilone showed low susceptibility to 
several important cellular mechanisms that render multiple 
classes of therapy ineffective, including elevated expression 
of drug efflux transporter proteins (eg, P-glycoprotein and 
multiple-resistance protein-1).15
Clinically, ixabepilone has exhibited single-agent activity 
against a broad range of tumors, including breast cancer, 
nonsmall cell lung carcinoma, pancreatic cancer, renal cell 
cancer, prostate cancer, and lymphoma.15 Furthermore, as a 
single agent or in combination with capecitabine, ixabepilone 
has demonstrated clinical efficacy across the spectrum of breast 
cancer treatment in a number of studies.22–29 This article reviews 
the clinical evidence that supports the use of ixabepilone in 
the treatment of various stages of breast cancer.
Ixabepilone in primary untreated 
breast cancer
Neoadjuvant ixabepilone has been evaluated in primary 
untreated breast cancer in a phase II trial involving women 
with previously untreated, invasive, stage IIA–IIIB breast 
cancer (n = 164).22 Patients with tumors at least 3 cm in 
diameter were administered an intravenous (IV) infusion 
of ixabepilone at 40 mg/m2 over 3 hours on day 1 of a 
21-day cycle for up to 4 cycles prior to surgery. Surgery was 
followed by anthracycline-based adjuvant chemotherapy, 
radiotherapy, or tamoxifen, as indicated. A pathologic 
complete response (pCR) in the breast was achieved in 18% 
(29/161) of evaluable patients, with a higher response rate 
(26%; 11/42) in patients with tumors that were negative for 
the estrogen receptor (ER), progesterone receptor (PgR), and 
HER2 (ie, the so-called “triple-negative” patients). The pCR 
rates in the breast and axilla were 11% in all treated patients 
and 19% in the triple-negative subset.
Interestingly, a retrospective microarray analysis of 
tissue samples from patients from this study revealed that 
the triple-negative patients expressed higher levels of 
βIII-tubulin. Moreover, a receiver operating characteristics 
(ROC) analysis showed that, in the overall population, 
βIII-tubulin expression was predictive of response to 
ixabepilone.30 These results might partially explain the higher 
response in patients with triple-negative disease, although 
further characterization of this phenomenon is needed. In this 
neoadjuvant study, grade 3 or 4 neutropenia was reported by 
13% of patients and grade 3 or 4 neuropathy by 2%.
Although only limited conclusions can be drawn by 
comparing results from different studies, the pCR rates from 
this phase II trial compared favorably with those observed 
in trials of other regimens, which ranged from 3% to 20% 
(Table 1).22,31–35 Trials at several institutions are expanding 
the investigation of ixabepilone in patients with primary 
untreated breast cancer. For instance, in an ongoing phase II 
study, the efficacy and tolerability of neoadjuvant ixabepilone 
is being compared with paclitaxel when administered after 
doxorubicin and cyclophosphamide in patients with early 
breast cancer.36
Ixabepilone trials  
as an adjuvant therapy
To date, there is no published data to support the use 
of ixabepilone in the adjuvant setting. A randomized, 
open-label, phase III trial is underway to evaluate the 
benefit of a sequential regimen of FEC 100 (5-fluorouracil, 
epirubicin, and cyclophosphamide) and ixabepilone in 
the adjuvant treatment of triple-negative or HER2- and 
PgR-negative node-positive or -negative breast cancer.37 
Another ongoing phase III study is comparing single-agent 
ixabepilone with single-agent paclitaxel administered Cancer Management and Research 2010:2 171
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after doxorubicin and cyclophosphamide for the adjuvant 
treatment of triple-negative, early-stage breast cancer.38
Ixabepilone in locally advanced  
and metastatic disease
Ixabepilone has been evaluated in patients with locally 
advanced and metastatic breast cancer in a series of 
phase II trials23–27,39,40 (as a single agent [Table 2]23–27 and in 
combination with various cytotoxic and targeted agents) and 
phase III trials (in combination with capecitabine).28,29
Taxane-naïve patients
Several studies have suggested that ixabepilone has signifi-
cant antitumor activity in patients who have not received 
prior taxane therapy but have received prior anthracycline 
therapy. For example, Denduluri and colleagues evaluated 
the use of daily ixabepilone as a single agent in patients 
with metastatic breast cancer who had not received taxanes 
in the adjuvant or metastatic setting.23 This study placed 
no limits on prior therapy. Of the 23 patients enrolled in 
this study, 70% had received prior chemotherapy, includ-
ing anthracyclines and/or capecitabine, and 61% of those 
with hormone receptor-positive disease had been treated 
with prior hormone therapy. Ixabepilone at 6 mg/m2 was 
administered as a 1-hour IV infusion on the first 5 consecu-
tive days of a 21-day cycle until unacceptable toxic effects 
or disease progression occurred. Patients received between 
2 and 22 treatment cycles (median, 8 cycles); four patients 
required dose reductions owing to adverse events. Thirteen 
patients achieved a partial response (PR), giving an objec-
tive response rate (ORR) of 57%, with a median duration 
of response of 5.6 months. Another six patients (26%) 
achieved stable disease (SD) for 6 weeks or more. Median 
time-to-progression (TTP) in all patients was 5.5 months. 
Of the five patients who received ixabepilone as first-line 
metastatic therapy, three achieved a PR and one had SD. Of 
the 12 patients who had received prior anthracyclines, seven 
had a PR and four had SD. Treatment was generally well 
tolerated, with most adverse events being mild or moderate 
in severity. Grade 3 and 4 adverse events included fatigue 
(13%), nausea (9%), motor neuropathy (4%), and neutro-
penia (22%).
Roché and associates examined the use of first-line 
ixabepilone monotherapy at 40 mg/m2 as a 3-hour IV infusion 
on day 1 of a 21-day cycle among 65 patients with metastatic 
breast cancer pretreated with adjuvant anthracyclines.26 
Although patients were receiving first-line treatment for 
metastatic disease, they had an extensive tumor burden; most 
had involvement of at least two tumor sites (77%) and/or 
visceral metastases (85%). Twenty-seven patients achieved a 
PR, producing an ORR of 41.5%, with a median duration of 
8.2 months. SD occurred in 23 patients (35%), 11 of whom 
were progression free for at least 6 months. In the total study 
population, median TTP was 4.8 months, and median overall 
survival (OS) was 22 months. It should be noted that although 
no patients had received taxanes for metastatic disease, 
17% of patients had been exposed to taxanes as part of an 
adjuvant regimen. No analysis of response based on prior 
taxane exposure was reported. Treatment-related adverse 
events were mostly grade 1 or 2 in severity and included 
alopecia (92%), sensory neuropathy (71%), fatigue (68%), 
myalgia (65%), and nausea (54%). Hematologic toxicities 
did not result in treatment discontinuation or death, with only 
7 patients requiring a delay in dosing. The main grade 3 and 
4 toxicities included sensory neuropathy (20%), neutropenia 
(58%), and leukopenia (50%).
Table 1 Pathologic response rates in single-agent neoadjuvant phase II trials for early breast cancer22,31–35
Reference Patients, n Treatment Dose and schedule Number of cycles pCR, %
Baselga et al22 161 Ixabepilone 40 mg/m2 IV over 3 hours;  
every 3 weeks
4 18
Fisher et al31 1523 Doxorubicin/  
cyclophosphamide
60 and 600 mg/m2, respectively;  
schedule not reported
4 13
Gradishar32 33 Docetaxel 100 mg/m2 IV over 1 hour;  
every 3 weeks
4 3
Buzdar et al33 87 Paclitaxel 250 mg/m2 IV over 24 hours;  
every 3 weeks
4 9
Amat et al34 80 Docetaxel 100 mg/m2 IV over 1 hour;  
every 3 weeks
6 20
Estévez et al35 56 Docetaxel 40 mg/m2 IV over 30 minutes;  
weekly for 6 weeks of an 8-week cycle
12 16
Abbreviation: pCR, pathologic complete response; IV, intravenous.Cancer Management and Research 2010:2 172
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Although these phase II monotherapy studies involved 
small sample sizes and did not include a control arm, 
the observed response rates and survival outcomes with 
ixabepilone are encouraging for the treatment of patients with 
prior exposure to anthracyclines, even among those with an 
extensive tumor burden.
Clinicians will be inclined to ask how ixabepilone 
performs in comparison to the taxanes, therefore broad 
comparisons between separate trials suggest that the results 
with ixabepilone are similar to outcomes achieved in phase 
III studies that evaluated docetaxel or paclitaxel in patients 
with advanced breast cancer that has progressed during 
anthracycline therapy (ORRs, 25% to 59%; TTP/PFS, 
3.6 to 19.0 months; OS durations, 11.4 to 34.0 months).41–43 In 
addition, a recent phase II trial suggests that, like paclitaxel, 
ixabepilone is also effective given on a weekly basis 
(15 mg/m2) with trastuzumab (2 mg/kg, after a 4 mg/kg 
loading dose) and carboplatin (area under curve [AUC], 
2) as first-line therapy in HER2-positive patients.39 Among 
59 treated patients, 44% achieved an objective response; 
median TTP and OS were 8.2 months and 34.7 months, 
respectively. These results are comparable to phase III 
outcomes for the combination of every-3-week paclitaxel 
and carboplatin plus weekly trastuzumab (ORR, 52%; PFS, 
10.7 months; OS, 35.7 months),44 even though approximately 
one-third of patients in the ixabepilone trial had received 
taxanes in the neoadjuvant or adjuvant setting compared to 
none in the paclitaxel trial.
Data directly comparing ixabepilone to the taxanes in the 
first-line setting has only recently become available, when a 
randomized phase II study evaluated the combination of ixabepi-
lone and bevacizumab at two doses and schedules (ixabepilone 
16 mg/m2 on days 1, 8, and 15 plus bevacizumab 10 mg/kg every 
2 weeks [n = 46] or ixabepilone 40 mg/m2 plus bevacizumab 
15 mg/kg every 3 weeks [n = 45]) in comparison to paclitaxel 
(90 mg/m2 on days 1, 8, and 15) plus bevacizumab (10 mg/kg 
every 2 weeks [n = 32]) as first-line therapy for metastatic 
breast cancer.40 Although the numbers of patients in each arm 
were small, efficacy outcomes for both the weekly (ORR, 50%; 
24-week PFS, 75%) and the every-3-week (ORR, 71%; 24-
week PFS, 86%) ixabepilone regimens appeared to be at least 
comparable to those seen with weekly paclitaxel (ORR, 56%; 
24-week PFS, 94%) when combined with bevacizumab. Toxicity 
profiles were also similar, although rates of grade 3/4 neutropenia 
were higher for every-3-week ixabepilone (55%) than for weekly 
ixabepilone (11%) or paclitaxel (22%).40 Results from an ongo-
ing phase III trial may provide a more definitive comparison of 
these regimens (CALGB 40502; NCT00785291).
Patients with prior exposure to taxanes
Options for second and subsequent lines of chemotherapy for 
metastatic breast cancer are especially limited for patients 
with innate or acquired taxane resistance. Single-agent ixa-
bepilone has proven effective as a second-, third-, or fourth-
line option in heavily-pretreated and multidrug-resistant 
patients. In a registrational study conducted for FDA approval, 
Perez and coworkers evaluated ixabepilone at 40 mg/m2 as 
a 3-hour IV infusion on day 1 of every 21-day cycle in 126 
patients with anthracycline-, taxane-, and/or capecitabine-
resistant metastatic breast cancer.25 Patients had baseline 
disease characteristics that included multiple disease sites 
and visceral disease affecting the liver and lung. In addition, 
one-third of patients had triple-negative disease. Despite the 
poor prognosis of the population as a whole, 11.5% of 113 
evaluable patients achieved an independent radiology review 
(IRR)-assessed objective response, with a median duration 
of response of 5.7 months. In addition, 50% of patients 
achieved IRR-assessed SD with median PFS and OS dura-
tions of 3.1 months and 8.6 months, respectively. Grade 3 
and 4 nonhematologic adverse events included peripheral 
sensory neuropathy (14%) and fatigue/asthenia (14%). In 
most instances, neuropathy occurred early on in treatment and 
was generally reversible with dose reductions within a median 
time of 5.4 weeks.45 Grade 3 or 4 neutropenia and leukopenia 
occurred in 54% and 49% of patients, respectively, but febrile 
neutropenia and infection were uncommon (reported in 4 and 
3 patients, respectively).25
Low and colleagues determined the efficacy and toler-
ability of ixabepilone in 37 women with locally advanced or 
metastatic breast cancer previously treated with taxanes in 
the neoadjuvant, adjuvant, or metastatic setting.24 At baseline, 
patients were heavily pretreated, with 43% having received 
between three and nine prior chemotherapy regimens for 
metastatic disease and all patients having received at least 
two cycles of a paclitaxel- or docetaxel-containing regimen. 
Ixabepilone was administered as a 1-hour IV infusion of 
6 mg/m2 on the first 5 consecutive days of a 21-day cycle until 
unacceptable toxic effects or disease progression occurred. 
One patient achieved a pCR and seven achieved a PR for an 
ORR of 22%, with median response duration of 3.7 months. 
Another 35% of patients achieved SD for 6 weeks. Interest-
ingly, the SD responses were achieved in patients who had 
experienced disease progression while receiving taxanes and 
in patients who had been previously treated with doxorubicin, 
capecitabine, and a taxane, suggesting that ixabepilone was 
able to circumvent tumor resistance mechanisms in these 
patients. In the entire study population, median TTP was Cancer Management and Research 2010:2 174
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2.5 months. Grade 3 and 4 toxicities included neutropenia 
(35%), febrile neutropenia (14%), fatigue (14%), diarrhea 
(11%), nausea/vomiting (5%), myalgia/arthralgia (3%), 
and sensory neuropathy (3%). One patient withdrew from 
the study because of grade 3 sensory neuropathy, and one 
patient withdrew because of prolonged grade 2 sensory 
neuropathy.
Thomas and colleagues investigated the use of ixabepilone 
in patients with metastatic breast cancer that had progressed 
during, or within 4 months of taxane therapy (6 months 
if received in the adjuvant setting).27 In this study, 
49 patients were administered ixabepilone at 40 mg/m2 as 
a 3-hour IV infusion on day 1 of a 21-day cycle. Patients 
were heavily pretreated (86% had received two or more 
prior chemotherapy regimens) and had a substantial tumor 
burden (84% had at least two involved disease sites, and 
84% had visceral disease). The ORR was 12% (6 PRs), 
with a median duration of response of 10.4 months. All 
responders had extensive disease at baseline that had pro-
gressed after multiple prior therapies. Forty-one percent of 
patients achieved SD, with a median TTP of 2.2 months and 
median OS of 7.9 months. Most adverse events were mild-
to-moderate in severity. The most common adverse events 
of any grade included fatigue (76%), nausea (57%), pain 
(65%), and sensory neuropathy (all grades, 63%; grade 3, 
12%; grade 4, 0%). Sensory neuropathy was largely reversible 
and responsive to ixabepilone dose reductions.
A combination of ixabepilone plus capecitabine has 
also been studied in patients with metastatic breast cancer 
previously treated with anthracyclines or a taxane.28,29 
Promising efficacy and safety results from a phase I/II trial46 
led to initiation of a pivotal phase III trial (BMS 046) of 
ixabepilone (40 mg/m2 as a 3-hour IV infusion on day 
1 every 21 days) plus capecitabine (2000 mg/m2 on days 
1 to 14 of a 21-day cycle) compared with capecitabine alone 
(2500 mg/m2 on days 1 to 14 of a 21-day cycle) in 752 patients 
with locally advanced or metastatic breast cancer that had 
progressed after treatment with anthracyclines and taxanes.28 
In its entrance criteria, the study employed a strict definition 
of taxane resistance, requiring patients to have progressed 
during treatment or relapsed within 4 months of the last dose 
in the metastatic setting or within 12 months in the adjuvant 
setting. In general, patients were heavily pretreated and had a 
heavy burden of disease; nearly 50% of patients had received 
2 prior regimens in the metastatic setting, 90% of patients 
had metastases at two or more sites, and 84% had visceral 
disease involving the liver and/or lung. In this study, adding 
ixabepilone to capecitabine achieved an IRR-assessed ORR 
of 35% compared with 14% for capecitabine monotherapy, 
and an investigator-assessed ORR of 42% compared with 
23% for capecitabine monotherapy. Median durations of 
response for the two treatment arms were 6.4 and 5.6 months, 
respectively. The median IRR-assessed PFS was significantly 
longer for the combined regimen (5.8 months) than for 
capecitabine alone (4.2 months), resulting in a 25% risk 
reduction for disease progression with combined therapy 
(hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.64 
to 0.88; P = 0.003; Figure 1).28 Consistent with this result, 
the investigator-assessed median PFS was longer for the 
combined regimen than for capecitabine alone (5.3 vs 3.8 
months; P = 0.0011). This improvement in disease progression 
was maintained in a sensitivity analysis requested by the 
FDA. When patients who received subsequent therapy before 
disease progression were censored for PFS at the last tumor 
assessment date, ixabepilone plus capecitabine still prolonged 
PFS compared with capecitabine alone (5.7 vs 4.1 months; 
HR, 0.69; 95% CI, 0.58 to 0.83; P  0.0001).47 Compared 
with capecitabine alone, ixabepilone plus capecitabine was 
associated with a higher rate of grade 3 or 4 sensory neuropa-
thy (21% vs 0%), fatigue (9% vs 3%), and neutropenia (68% 
vs 11%), as well as an increased rate of neutropenia-related 
death as a result of toxicity (3% vs 1%, with patients with 
liver dysfunction [grade 2 liver function tests] at greater 
risk).28
A larger confirmatory phase III trial (BMS 048) in patients 
who were pretreated and/or resistant to anthracyclines and 
taxanes (n = 1221) provided further evidence that ixabepilone 
plus capecitabine consistently improved PFS compared with 
capecitabine alone (6.2 vs 4.4 months).29 Notably, 50% of the 
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Figure 1 Independent radiology review-assessed PFS durations after treatment with 
ixabepilone plus capecitabine compared with capecitabine alone in women with locally 
advanced or metastatic breast cancer that had progressed after anthracycline and 
taxane treatment.28 Copyright © 2007. Reproduced with permission from Thomas ES, 
Gomez HL, Li RK, et al. lxabepilone plus capecitabine for metastatic breast cancer pro-
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patients in the confirmatory trial met the resistance criteria 
utilized in the pivotal trial.
Neither phase III study showed a significant difference 
in median OS between the two treatment arms; however, 
adjusting for prognostic factors in a preplanned analysis, 
combination therapy significantly reduced the risk of death 
by about 15% (P = 0.0803 for BMS 046; P = 0.0231 for 
BMS 048).29 Furthermore, as a part of these phase III studies, 
prospectively defined subset analyses revealed statistically 
significant improvements in PFS when the combination of 
ixabepilone and capecitabine was used as first-line metastatic 
therapy (after having received anthracyclines and/or taxanes 
in the adjuvant setting) and in triple-negative patients.48–50 
Patients who received ixabepilone plus capecitabine as 
first-line therapy experienced a 54% reduction in the estimated 
risk of disease progression with combination therapy.48 Taken 
together, these results showed that ixabepilone in combination 
with capecitabine has superior clinical efficacy to capecitabine 
alone in patients with metastatic disease pretreated or resistant 
to anthracyclines and resistant to taxanes, a population with 
limited effective treatment options.
Safety and tolerability  
of ixabepilone
Ixabepilone has a manageable safety profile in patients 
with all stages of breast cancer, even in those with 
extensive or heavily pretreated disease (Table 3).23–28 As 
mentioned, neutropenia, sensory neuropathy, fatigue, 
arthralgias, myalgias, and stomatitis are the main toxic 
effects associated with this agent.22–29,46 Ixabepilone-related 
adverse events are usually manageable through dose reduc-
tions or delays or with supportive care. Importantly, the 
toxicity profile of ixabepilone does not appear to overlap 
with that of capecitabine,28, 29 bevacizumab,40 or trastu-
zumab.39
Currently, the approved dose and schedule of ixabepilone 
(as monotherapy or with capecitabine) is 40 mg/m2 
administered IV every 3 weeks. Ongoing studies are evaluating 
the clinical profile of ixabepilone when administered weekly. 
An interim safety analysis of one such study, a randomized 
phase II trial comparing ixabepilone at the approved dose and 
schedule to ixabepilone 16 mg/m2 given on days 1, 8, and 
15 of a 28-day cycle, suggested that although both sched-
ules were well tolerated among patients (all had advanced 
metastatic breast cancer and three-quarters had received prior 
therapy in the metastatic setting), the weekly schedule was 
associated with a lower overall incidence of adverse events, 
particularly grade 3/4 peripheral neuropathy.51
Although neutropenia is frequently associated with 
ixabepilone therapy, the rate of febrile neutropenia is 
generally low. Hematologic toxicity is easily managed by 
dose reduction or by use of hematologic growth factors, 
but ixabepilone should not be administered until neu-
trophil counts are at least 1,500 cells/mm3 and platelet 
counts at least 100,000 cells/mm3.52 Furthermore, in the 
initial phase III trial of ixabepilone plus capecitabine, a 
higher rate of neutropenia-related deaths was reported in 
the combination-therapy group, particularly in patients 
with pre-existing hepatic insufficiency, than in the 
capecitabine-alone group.28 For this reason, ixabepilone 
in combination with capecitabine is contraindicated in 
patients with signs of moderate-to-severe liver dysfunction 
at baseline.52
Neurotoxicity is a major concern with microtubule-
stabilizing drugs like taxanes,53,54 and in clinical trials 
with locally advanced or metastatic breast cancer, the 
rates of grade 3 and 4 peripheral sensory neuropathy with 
ixabepilone therapy ranged from 0% to 21% (Table 3). 
Neuropathy was mainly sensory, cumulative, and reversible 
upon treatment modification or delay.54 For example, in the 
initial phase III study of ixabepilone plus capecitabine, 70 
of the 79 patients with grade 3 or 4 peripheral neuropathy 
had complete resolution or improvement of symptoms, with 
a median time to resolution to grade 1 or baseline severity 
of 6 weeks (Figure 2).54 In patients with grade 2 peripheral 
neuropathy lasting 7 days, the dose of ixabepilone should 
be reduced by 20%. Patients with grade 3 neuropathy 
lasting 7 days should also receive a 20% reduction in the 
dose of ixabepilone. Ixabepilone should be discontinued in 
patients who experience grade 3 neuropathy lasting 7 days 
or disabling neuropathy.52 In the initial phase III study of 
ixabepilone plus capecitabine, patients with persistent grade 
2 or 3 peripheral neuropathy received a median of three 
additional cycles after dose reduction. After dose reduction, 
peripheral neuropathy either improved or stabilized in most 
patients.28 Neurologic function tests may be of some value in 
predicting the risk of sensory neuropathy during ixabepilone 
therapy.55
As with any chemotherapeutic agent, the benefits 
associated with ixabepilone therapy should be care-
fully weighed against the risks. In the setting of locally 
advanced or metastatic breast, a positive benefit-to-risk 
profile for combination ixabepilone plus capecitabine was 
revealed in a quality adjusted time without symptoms or 
toxicities (Q-TWiST) analysis of the initial phase III trial.56 
This Q-TWiST analysis evaluated the trade-off between Cancer Management and Research 2010:2 176
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Table 3 Adverse events that occurred in 10% of clinical trials of ixabepilone for locally advanced or metastatic breast cancer23–28
Study Thomas et al28 Denduluri et al23 Roché et al26 Low et al24 Thomas et al27 Perez et al25
Dose/schedule Ixabepilone  
40 mg/m2  
every 3 weeks +  
capecitabine  
2000 mg/m2  
on days 1–14
Capecitabine  
2500 mg/m2 on  
days 1–14
Ixabepilone  
6 mg/m2 daily  
on days 1–5  
every 3 weeks
Ixabepilone  
40 mg/m2  
every 3 weeks
Ixabepilone  
40 mg/m2  
every 3 weeks
Ixabepilone  
40 mg/m2  
every 3 weeks
Ixabepilone 
40 mg/m2 
every 
3 weeks
Number of patients  
treated
369 368 23 65 37 49 126
Patient population Pretreated; resistant to  
anthracyclines  
and resistant to taxanes
No previous  
exposure to  
taxanes in  
adjuvant  
or metastatic  
setting
Previously treated  
with adjuvant  
anthracyclines
Previously 
treated  
with taxanes in  
neoadjuvant,  
adjuvant, or  
metastatic  
setting
Resistant to  
taxanes
Resistant to  
anthracy-
clines,  
taxanes, and   
capecitabine
Nonhematologic adverse events, % all grades (% grade 3/4)
Peripheral sensory  
neuropathy
64 (21) 16 (0) 52 (0) 71 (20) 54 (3) 63 (12) 60 (14)
Fatigue/asthenia 64 (16) 30 (4) 78 (13) 68 (6) 65 (14) 76 (27) 50 (14)
Myalgia/arthralgia 53 6 30 97 51 84 49
Alopecia 31 3 87 92 54 43 48
Nausea 53 40 61 54 54 57 42
Stomatitis/mucositis/ 
pharyngitis
33 21 – 32 – 28 29
Vomiting 39 24 39 26 22 41 29
Diarrhea 44 39 48 29 35 31 22
Rash – – – 22 – 12 –
Musculoskeletal pain – – – – – – 20
Anorexia 31 14 – 18 – 18 19
Constipation 22 6 56 20 27 20 16
Nail changes 20 8 56 17 30 8 9
Fever – – – 14 – 16 –
Abdominal pain/ 
cramping
– – – 8 – 10 13
Headache – – – 14 – – 11
Neuropathic pain – – – 12 – 8 –
Pain, other – – – 14 – 65 8
Infection without  
neutropenia
– – – 14 – 12 –
Infection/febrile  
neutropenia
– – 0 6 14 6 –
Motor neuropathy 16 0.3 9 6 – – 10
Taste disturbance/ 
dysgeusia
= = 65 11 32 – 6
Hand-foot syndrome 64 62 – – – – –
Hematologic adverse events, % all grades (% grade 3/4)
Neutropenia 89 (67) 43 (11) 87 (22) 89 (58) 68 (35) N/A (53) 79 (54)
Leukopenia 90 (57) 54 (6) – 92 (50) – 6 (2) 90 (49)
Anemia 90 (9) 70 (4) 83 (0) 92 (3) 73 (0) 6 (4) 84 (8)
Thrombocytopenia 54 (8) 31 (4) 52 (4) 40 (0) 41 (8) – 44 (8)Cancer Management and Research 2010:2 177
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toxicity and PFS by taking into account the time spent by 
each patient with or without grade 3 or 4 toxicity prior to 
  progression and the time from progression to death or end 
of follow-up. Remarkably, quality adjusted mean survival 
was significantly greater for ixabepilone plus capecitabine 
than it was for capecitabine alone (P = 0.0227), with a 
3.8-week improvement with ixabepilone plus capecitabine 
over capecitabine alone.
Conclusions
The novel chemotherapeutic agent ixabepilone exhibits 
reduced susceptibility to several important tumor survival 
mechanisms that limit the efficacy of taxanes and 
anthracyclines. Ixabepilone has demonstrated efficacy in 
patients across the breast cancer spectrum of early-stage 
to advanced disease, including patients with extensive, 
aggressive, and heavily pretreated tumors and those with 
resistance to several other agents. Ixabepilone is approved 
for the treatment of patients with locally advanced or 
metastatic breast cancer as monotherapy after failure of an 
anthracycline, a taxane, and capecitabine, and in combina-
tion with capecitabine after failure of an anthracycline and 
a taxane. Ixabepilone is also being investigated in combina-
tions with several other cytotoxic and biologic agents, and 
preliminary studies point toward efficacy in combination 
with bevacizumab or trastuzumab that is comparable to that 
of paclitaxel.
Preliminary data also suggest promising efficacy with 
ixabepilone in the neoadjuvant setting, and studies are 
underway investigating the benefits of ixabepilone in the 
adjuvant setting. The fact that βIII-tubulin appears to 
be particularly upregulated in triple-negative breast tumors 
may render ixabepilone more active in this subgroup of 
patients, an observation in need of additional clinical vali-
dation.
The manageable safety profile of ixabepilone supports 
its clinical utility, as adverse events can usually be managed 
with a dose reduction or delay, or with appropriate supportive 
care. Response appeared to be better and toxic effects were 
milder when ixabepilone was used earlier in the treatment 
course (eg, in the first- or second-line setting) in patients who 
were less heavily pretreated.
The phase III studies reveal that capecitabine does not 
exacerbate ixabepilone-related toxicities, or vice versa. 
Moreover, adverse events were manageable and responsive 
to intervention regardless of whether ixabepilone was given 
alone or with capecitabine. However, as is to be expected 
with any cytotoxic chemotherapy, the incidence and 
severity of toxicities was lower when ixabepilone was used 
as monotherapy. These observations highlight the need to 
evaluate candidates for ixabepilone therapy on a case-by-case 
basis to determine whether the patient may experience the 
greatest overall benefit from monotherapy or from more 
aggressive combination therapy. Importantly, ixabepilone still 
demonstrated reasonable efficacy when used as monotherapy, 
even in patients with a heavy disease burden, documented 
resistance to several other classes of chemotherapy, or 
aggressive tumors (eg, triple-negative disease).
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Figure 2 Resolution of grade 3 or 4 peripheral neuropathy in patients who received ixabepilone plus capecitabine.54 Copyright © 2008.
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For the reasons discussed above, ixabepilone represents a 
clinically useful addition to the therapeutic agents available 
for patients with resistant advanced breast cancer that help 
to extend PFS in patients with limited treatment options. 
Ongoing investigations in early-stage disease should provide 
insight as to how this novel agent could be effectively 
integrated into this setting.
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